Year To Quarter End Consolidated Statement Of Income

Modalis Therapeutics Corporation - Filing #7312187

Concept 2024-01-01 to
2024-06-30
2023-01-01 to
2023-06-30
Year to quarter end consolidated statement of income
Statement of income
Selling, general and administrative expenses
Remuneration for directors (and other officers)
25,590,000 JPY
23,130,000 JPY
Selling, general and administrative expenses
122,437,000 JPY
138,360,000 JPY
Operating profit (loss)
-838,956,000 JPY
-1,044,792,000 JPY
Non-operating income
Interest income
8,000 JPY
14,000 JPY
Non-operating income
63,052,000 JPY
54,660,000 JPY
Non-operating expenses
Interest expenses
2,057,000 JPY
2,212,000 JPY
Non-operating expenses
4,248,000 JPY
5,343,000 JPY
Ordinary profit (loss)
-780,152,000 JPY
-995,474,000 JPY
Extraordinary losses
Impairment losses
188,000 JPY
37,146,000 JPY
Extraordinary losses
188,000 JPY
37,146,000 JPY
Profit (loss) before income taxes
-780,340,000 JPY
-1,032,620,000 JPY
Income taxes - current
606,000 JPY
607,000 JPY
Income taxes
606,000 JPY
607,000 JPY
Profit (loss)
-780,946,000 JPY
-1,033,228,000 JPY
Profit attributable to
Profit (loss) attributable to owners of parent
-780,946,000 JPY
-1,033,228,000 JPY
Other comprehensive income
Foreign currency translation adjustment
8,801,000 JPY
-1,676,000 JPY
Other comprehensive income
8,801,000 JPY
-1,676,000 JPY
Comprehensive income
-772,145,000 JPY
-1,034,904,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
-772,145,000 JPY
-1,034,904,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.